View in EDS HTML Full Text PDF Full Text

Acquired resistance to PD-L1 inhibition enhances a type I IFN-regulated secretory program in tumors.

Saved in:
Bibliographic Details
Title: Acquired resistance to PD-L1 inhibition enhances a type I IFN-regulated secretory program in tumors.
Authors: Shi Y; Department of Experimental Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA., McKenery A; Department of Cancer Genetics and Genomics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA., Dolan M; Department of Experimental Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA., Mastri M; Department of Cancer Genetics and Genomics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA., Hill JW; Jacobs School of Medicine and Biomedical Sciences, SUNY at Buffalo, Buffalo, USA., Dommer A; Department of Cancer Genetics and Genomics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA., Benzekry S; Computational Pharmacology and Clinical Oncology (COMPO), Inria Sophia Antipolis-Méditerranée, Centre de Recherches en Cancérologie de Marseille, Inserm U1068, CNRS UMR7258, Institut Paoli-Calmettes, Faculté de Pharmacie, Aix-Marseille University, Marseille, France., Long M; Department of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA., Abrams SI; Department of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA., Puzanov I; Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA., Ebos JML; Department of Experimental Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA. John.Ebos@RoswellPark.org.; Department of Cancer Genetics and Genomics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA. John.Ebos@RoswellPark.org.; Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA. John.Ebos@RoswellPark.org.
Source: EMBO reports [EMBO Rep] 2025 Jan; Vol. 26 (2), pp. 521-559. Date of Electronic Publication: 2024 Dec 11.
Publication Type: Journal Article
Journal Info: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 100963049 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1469-3178 (Electronic) Linking ISSN: 1469221X NLM ISO Abbreviation: EMBO Rep Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 39663510
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Acquired resistance to PD-L1 inhibition enhances a type I IFN-regulated secretory program in tumors.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Shi+Y%22">Shi Y</searchLink>; Department of Experimental Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA.<br /><searchLink fieldCode="AU" term="%22McKenery+A%22">McKenery A</searchLink>; Department of Cancer Genetics and Genomics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA.<br /><searchLink fieldCode="AU" term="%22Dolan+M%22">Dolan M</searchLink>; Department of Experimental Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA.<br /><searchLink fieldCode="AU" term="%22Mastri+M%22">Mastri M</searchLink>; Department of Cancer Genetics and Genomics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA.<br /><searchLink fieldCode="AU" term="%22Hill+JW%22">Hill JW</searchLink>; Jacobs School of Medicine and Biomedical Sciences, SUNY at Buffalo, Buffalo, USA.<br /><searchLink fieldCode="AU" term="%22Dommer+A%22">Dommer A</searchLink>; Department of Cancer Genetics and Genomics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA.<br /><searchLink fieldCode="AU" term="%22Benzekry+S%22">Benzekry S</searchLink>; Computational Pharmacology and Clinical Oncology (COMPO), Inria Sophia Antipolis-Méditerranée, Centre de Recherches en Cancérologie de Marseille, Inserm U1068, CNRS UMR7258, Institut Paoli-Calmettes, Faculté de Pharmacie, Aix-Marseille University, Marseille, France.<br /><searchLink fieldCode="AU" term="%22Long+M%22">Long M</searchLink>; Department of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA.<br /><searchLink fieldCode="AU" term="%22Abrams+SI%22">Abrams SI</searchLink>; Department of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA.<br /><searchLink fieldCode="AU" term="%22Puzanov+I%22">Puzanov I</searchLink>; Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA.<br /><searchLink fieldCode="AU" term="%22Ebos+JML%22">Ebos JML</searchLink>; Department of Experimental Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA. John.Ebos@RoswellPark.org.; Department of Cancer Genetics and Genomics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA. John.Ebos@RoswellPark.org.; Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA. John.Ebos@RoswellPark.org.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22100963049%22">EMBO reports</searchLink> [EMBO Rep] 2025 Jan; Vol. 26 (2), pp. 521-559. <i>Date of Electronic Publication: </i>2024 Dec 11.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Nature+Publishing+Group%22">Nature Publishing Group </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>100963049 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1469-3178 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%221469221X%22">1469221X </searchLink><i>NLM ISO Abbreviation: </i>EMBO Rep <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=39663510
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1038/s44319-024-00333-0
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 521
    Titles:
      – TitleFull: Acquired resistance to PD-L1 inhibition enhances a type I IFN-regulated secretory program in tumors.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Shi Y
      – PersonEntity:
          Name:
            NameFull: McKenery A
      – PersonEntity:
          Name:
            NameFull: Dolan M
      – PersonEntity:
          Name:
            NameFull: Mastri M
      – PersonEntity:
          Name:
            NameFull: Hill JW
      – PersonEntity:
          Name:
            NameFull: Dommer A
      – PersonEntity:
          Name:
            NameFull: Benzekry S
      – PersonEntity:
          Name:
            NameFull: Long M
      – PersonEntity:
          Name:
            NameFull: Abrams SI
      – PersonEntity:
          Name:
            NameFull: Puzanov I
      – PersonEntity:
          Name:
            NameFull: Ebos JML
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 01
              Text: 2025 Jan
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 1469-3178
          Numbering:
            – Type: volume
              Value: 26
            – Type: issue
              Value: 2
          Titles:
            – TitleFull: EMBO reports
              Type: main
ResultId 1